Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting

By LabMedica International staff writers
Posted on 17 Oct 2022

The fastest SARS-CoV-2 antigen test, that offers a reliable and easy-to-use testing solution for COVID-19 infection, is now available in Europe and any countries accepting the CE mark.

MedMira Inc. (Halifax, NS, Canada) has developed its first rapid antigen test, the VYRA COVID-19 Antigen Test (VYRA COVID-19), utilizing its patented Rapid Vertical Flow (RVF) technology. The technology facilitates the formation of highly specific antigen-antibody reactions allowing specific biomarkers in many sample types, including human whole blood, serum or plasma, to be captured and visualized on a unique membrane. The simple test procedure involves adding the specimen to the device and allowing it to flow through the membrane. If the specimen contains the target antibodies or antigens, they are captured on the test membrane and can be visually interpreted immediately after the addition of a detection reagent. The technology platform is unique in its ability to detect multiple biomarkers specific to several diseases using a single cartridge.

VYRA COVID-19, built using MedMira’s RVF technology, detects antigens specific for the nucleocapsid region of SARS-CoV-2, the causative agent of COVID-19, and can determine an active infection in less than three minutes. VYRA COVID-19 nasal swab based test is designed to be non-invasive and user-friendly, making it more suitable for any setting. Designed to detect SARS-CoV-2 virus in swab samples, VYRA COVID-19 directly addresses the need for a fast, reliable, and easy-to-use testing solution. MedMira has received the CE mark for its VYRA COVID-19, which is now the fastest SARS-CoV-2 antigen test available.

"Whereas VYRA COVID-19 provides a high-quality single antigen test for the detection of SARS-CoV-2 designed for customers who are worried about a COVID-19 infection, our up-coming VYRA CoV2Flu Antigen Test will further complement our product offering to customers who wish to have a result for COVID-19 or Flu A or Flu B immediately," said Hermes Chan, CEO of MedMira Inc. "With the increasing infection rates during the next few months and the need for quality rapid testing solutions, MedMira's VYRA COVID-19 is the fastest and most reliable answer. We anticipate our CE mark for the VYRA CoV2Flu and REVEALCOVID-19 Nab-Y Neutralizing Antibody Test in the coming weeks and with it are able to offer our distribution partners a complete set of COVID-19 related products."

Related Links:
MedMira

Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Amoebiasis Test
ELI.H.A Amoeba
New
Nutating Mixer
Enduro MiniMix
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.